|
Gary Burbach joined Thoratec Corporation as president and chief executive officer in January 2006 at which time he was appointed to the board of directors. In the role of president and CEO Burbach sets and leads the strategic and operating direction for the company including Thoratec's medical devices for circulatory support vascular grafts and point of care diagnostic testing. Burbach will draw on his extensive operating and strategic experience and expertise in developing markets for new medical technologies to broaden market adoption of Thoratec's cardiac assist devices while also solidifying the company's position as a world leader in hemodynamic restoration therapy.
Before joining Thoratec Burbach served as the president and chief executive officer of Digirad Corporation a leading provider of solid-stage imaging products and services to cardiologist offices hospitals and imaging centers. He continues to serve on the Digirad board of directors. Previously Burbach served for two years as president and chief executive officer of Bacchus Vascular Inc. an interventional cardiovascular device company.
Before that he spent seven years with Philips Nuclear Medicine starting at ADAC Laboratories where he spent four years and became president and general manager of the nuclear medicine division. After Philips Electronics acquired ADAC Burbach spent three years as chief executive officer of Philips Nuclear Medicine. He also spent six years with the consulting firm of McKinsey & Company Inc. where he was most recently a senior engagement manager in the firm's healthcare practice.
Burbach holds a bachelor's degree in industrial engineering from Stanford University and a master's degree in business administration from Harvard Business School. | 